Abstract：
This Radix study cum aims Melle to explore(HRPM)the on efficacy spleen differences deficiency between syndrome.modeling Astragali A Radix of Praeparata110cum rats Melle were(ARPM)randomized fatigue),and into rats Hedysari a Praeparata(n qi total irregular HRPM male diet,SD diarrhea,control were(n Yiqi=10)the=100).Pill group fied and model a modeling group,group Buzhong After(BYP)(through ARPM and the HRPM-H),classimedium-dose into(ARPM-M raised group,and high-dose(ARPM-H each and Rats BYP and under HRPM-M),normal and low-dose and(ARPM-L in and group HRPM-L)were groups,continuously10rats induced.were in group.the in group the were18.9,control given group were g·kg~(-1)conditions while those the the model Rats respectively in18.912.6,BYP kg~(-1)water extract,decoction those in ARPM/HRPM-H,the-M,dosage lasted and of-L groups treated the with control and model6.3group g·rewere motilin determined m L·kg~(-1)·day~(-1).days.of dose Spleen ARPM/HRPM of in water.morning,The at the10Rats spleen in index group thymus and index ceived equal calculated.(MTL),distilled tissue administration to15observe Then the and Routine of each group D-xylose,were was(IL-2),the subjected HE stainingγ(IFN-γ),lower to the pathological changes.(IgA),blood gastric indexes,mucosa index,interleukin-2group.interferon group immunoglobulin of A and spleen pepsin index,of in Ig A,IL-2spleen IFN-γ,control each MTL,levels Rats pepsin the in model(P<0.01),had higher levels routine(P<0.01),blood and indexes,more thymus lesions D-xylose,the and in index,level decreased HRPM-L of IL-2severe compared spleen with than the those model in group.thymus group.that(P<0.05group,P<0.01)index administration thymus groups Ig A or spleen as that and in spleen routine Except index,spleen the Ig A,index,group and were in in ARPM-M model group,group,index,indexes,P<0.01)and thymus MTL index,those in ARPM-L insignificantly Ig A,different pepsin from other those in the the blood index,compared IFN-γ,group,(P<0.05The D-xylose,model MTL,spleen and lesions high-dose in each administration administration groups group increased relieved.blood or comparison as of with HRPM in as the folARPM and the effect in and were white and result than ARPM and is of lows:(P stronger<0.05),of medium-dose high-dose HRPM HRPM on IL-2cell high-dose of(WBC)and count medium-dose the HRPM and corresponding doses than IFN-γmore ARPM the obvious effect(P<0.05of on evident(P<0.05of impact P<0.01),on low-dose between the on corresponD-xylose P<0.01),doses ding MTL doses than Meanwhile,in of or more high-dose,and medium-dose,difference HRPM the and indexes.corresponding there of ARPM in or IL-2no levels in the HRPM-L effect and two groups,on but conclusion,other the both functions IFN-γwas group no was difference more the than recovery that of the and ARPM-H between(IL-2,P<0.01;ARPM-L recovery HRPM the IFN-γ,P<0.05).HRPM-H and obvious therapeutic in rats group qi In ARPM dose have are certain equivalent,effects on with spleen function deficiency.the Specifically,is the better difference immunomodulatory of two at g·low kg~(-1).and but the promote immunomodulatory the of former rats significantly ARPM.than that between of the later two at in the dose>18.9HRPM promotion can of better digestion digestion absorption and may absorption due of than The immunoregulation and be to the difference in clinical medication.
摘要：
本研究旨在探讨梅乐（HRPM）脾虚证候之间的疗效差异。造模黄芪甲根110cum大鼠Melle（ARPM）随机疲劳，并放入大鼠HedysariaPraeparata（nqi总不规则HRPM雄性饮食，SD腹泻，对照组为(n益气=10)=100)。药丸组进行了建模，并对建模组进行了建模，B后（BYP）组（通过ARPM和HRPM-H），将中等剂量分为(ARPM-M升高组，和高剂量（每个ARPM-H和大鼠BYP和HRPM-M），正常和低剂量和（ARPM-L和HRPM-L组）组，连续诱导10只大鼠。在小组中。对照组为18.9，对照组为g·kg〜（-1）条件，而模型大鼠分别为18.912.6，BYPkg〜（-1）水提物，汤剂在ARPM/HRPM-H中，the-M,剂量持续，L组与对照组和模型组治疗6.3g·reware胃动素测定mL·kg〜（-1）·day〜（-1）。天。在水中的脾ARPM/HRPM的剂量。早晨,指数组10只大鼠脾脏胸腺和实验指数相等。(MTL),蒸馏组织给药15观察然后和常规每组D-木糖，是（IL-2），接受HE染色的γ（IFN-γ），降低到病理变化。(IgA),血液胃指数，粘膜指数,白细胞介素-2组。干扰素组免疫球蛋白A和脾胃蛋白酶指数，在IgA中，IL-2脾IFN-γ，控制每个MTL，模型大鼠胃蛋白酶水平（P＆lt;0.01），常规水平较高(P<0.01)，血液和指数，更多胸腺损伤D-木糖,在索引中，与模型组相比，IL-2重度脾脏的HRPM-L水平降低。胸腺组。(P<0.05组，P＆lt;0.01）指数给药胸腺组IgA或脾脏与脾脏常规相同，除指数外，脾IgA，索引,在ARPM-M模型组中，group,索引,索引，P<0.01)和胸腺MTL指数，ARPM-L中的那些不明显的IgA，胃蛋白酶与血液指数中的其他胃蛋白酶不同，比较IFN-γ，group,（P＆lt;0.05D-木糖，模型MTL，脾脏和病变高剂量给药组各给药组加重缓解。血液或与HRPM的比较，作为folARPM和效果，是白色的，结果比ARPM低：（P更强<0.05），中剂量高剂量HRPMHRPM对IL-2细胞高剂量（WBC）和计数中剂量HRPM及相应剂量比IFN-γ更有ARPM的明显影响（P＆lt;0.05of对明显（P＆lt;0.05of影响P＆lt;0.01），在低剂量下，对应的D-木糖P<0.01)，剂量与MTL剂量相比，同时，在或更高剂量中，和中等剂量，差异HRPM和索引。对应有ARPM或IL-2no水平的HRPM-L效应和两组，但结论是，其他两种功能IFN-γ组与ARPM-H组之间无差异（IL-2，P＆lt;0.01；ARPM-L恢复HRPMIFN-γ，P<0.05)。HRPM-H与明显治疗组大鼠气中ARPM剂量有一定的相当,对脾虚功能的影响。具体而言,在g·低kg〜（-1）时，两者的免疫调节差异较好。但显著促进前大鼠ARPM的免疫调节。在剂量18.9HRPM促进后两者之间可以更好地消化消化吸收，并且可能由于免疫调节而吸收而与临床用药的差异。
